vari
present
mild
sever
respiratori
failur
requir
mechan
ventil
howev
brazil
studi
clinic
present
diagnosi
infect
thu
author
present
articl
intend
review
main
viral
agent
caus
communityacquir
pneumonia
discuss
current
avail
diagnost
therapeut
method
pneumonia
de
origem
viral
uma
causa
prevalent
de
em
adulto
imunocompetent
tem
variada
ocasionando
desd
forma
leve
quadro
grave
de
com
necessidad
de
contudo
em
nosso
pouco
estudo
respeito
da
e
dessa
dessa
forma
os
autor
present
artigo
por
objetivo
revisar
os
principai
agent
virai
causador
de
pneumonia
na
comunidad
e
discutir
modalidad
e
atualment
pneumonia
remain
one
lead
caus
worldwid
morbid
mortal
spite
recent
advanc
field
diagnosi
estim
caus
infecti
agent
accur
identifi
less
case
brazil
major
studi
communityacquir
pneumonia
address
mostli
treatment
option
clinic
outcom
littl
known
local
microbiolog
standard
bacteria
remain
main
group
identifi
pathogen
actual
role
agent
fungi
protozoa
virus
yet
elucid
although
virus
identifi
import
caus
communityacquir
pneumonia
recent
mainli
due
pandem
greater
interest
role
agent
among
main
virus
caus
pneumonia
immunocompet
adult
influenza
viru
respiratori
syncyti
viru
rsv
adenoviru
human
parainfluenza
viru
hpiv
use
new
molecular
techniqu
allow
identif
virus
seldom
identifi
rhinoviru
metapneumoviru
coronaviru
review
aim
demonstr
modal
complementari
assess
current
avail
treatment
option
discuss
main
virus
implic
pathogenesi
communityacquir
pneumonia
immunocompet
adult
incid
viral
pneumonia
increas
significantli
recent
year
depend
agent
virul
patient
comorbid
present
may
rang
mild
selflimit
extrem
sever
case
respiratori
failur
result
laboratori
test
clinic
outcom
specif
pattern
identifi
imag
studi
consid
past
reliabl
identifi
infect
etiolog
nonspecif
import
diagnosi
remain
uncertain
thu
use
new
complementari
laboratori
test
higher
sensit
specif
contribut
definit
diagnosi
optim
treatment
diseas
howev
note
isol
agent
necessarili
mean
activ
infect
context
essenti
know
diagnost
option
identif
virus
well
limit
method
adequ
clinic
interpret
current
valid
method
defin
etiolog
viral
infect
summar
tabl
serolog
cultur
cytolog
evalu
rapid
detect
antigen
gene
amplif
techniqu
even
though
wide
avail
often
costli
virtual
virus
diagnos
serolog
howev
necessari
collect
pair
blood
sampl
acut
convalesc
phase
fourfold
titer
increas
relat
first
sampl
necessari
confirm
diagnosi
therefor
serolog
routin
use
shown
littl
use
acut
phase
diseas
titer
rare
increas
stage
studi
set
serolog
avail
mani
commun
respiratori
virus
adenoviru
rsv
season
influenza
viral
cultur
also
employ
respiratori
virus
long
time
necessari
obtain
result
disadvantag
well
need
specif
cultur
medium
perform
cultur
tissu
sampl
upper
andor
lower
airway
sputum
nasopharyng
bronchoalveolar
lavag
use
cytopath
effect
virus
observ
cell
cultur
format
syncyti
collect
multinucl
giant
cell
evid
viral
growth
subsequ
identif
specif
virus
cell
cultur
may
accomplish
immunofluoresc
techniqu
direct
indirect
nucleic
acid
probe
disadvantag
method
high
cost
low
avail
clinic
practic
also
low
yield
specif
agent
rsv
human
metapneumoviru
coronaviru
model
use
sampl
respiratori
tissu
also
secret
nasal
bronchoalveolar
lavag
techniqu
aim
identifi
nuclear
viru
dna
cytoplasm
viru
rna
inclus
normal
present
infect
cell
identif
presenc
inclus
confirm
diagnosi
disadvantag
method
low
sensit
absenc
find
rule
activ
diseas
rapid
test
perform
easili
obtain
specimen
nasal
swab
wash
enzymelink
immunosorb
assay
elisa
test
avail
pathogen
respiratori
virus
capabl
detect
viral
antigen
wherea
immunofluoresc
requir
intact
infect
cell
method
vari
sensit
specif
depend
agent
analyz
specif
season
influenza
instanc
approxim
sensit
howev
suspect
agent
influenza
viru
yield
extrem
low
therefor
recommend
confirm
infect
agent
antigen
remain
posit
week
less
sensit
viral
cultur
use
complementari
way
increas
diagnost
yield
sampl
materi
polymeras
chain
reaction
pcr
revers
transcriptasepolymeras
chain
reaction
rtpcr
techniqu
extrem
sensit
specif
detect
viru
presenc
examin
choic
respiratori
virus
avail
employ
togeth
aforement
diagnost
method
current
develop
techniqu
allow
knowledg
new
caus
agent
bronchiol
pneumonia
pediatr
adult
popul
method
appli
sampl
nasopharyng
bronchial
secret
swab
advantag
perform
bodi
fluid
blood
immunocompromis
patient
suspect
cytomegaloviru
infect
new
molecular
techniqu
call
multiplex
revers
transcriptas
polymeras
chain
reaction
mrtpcr
allow
rapid
detect
sever
respiratori
virus
influenza
b
rsv
b
hpiv
metapneumoviru
adenoviru
disadvantag
low
sensit
influenza
describ
method
nontyp
influenza
rna
viru
orthomyxovirida
famili
three
serotyp
b
c
describ
virus
respons
approxim
pneumonia
case
healthi
adult
higher
rate
found
outbreak
epidem
influenza
dissemin
aerosol
affect
entir
respiratori
tract
commonli
virul
serotyp
compris
number
subtyp
influenza
b
usual
caus
diseas
popul
confin
close
space
daycar
center
board
school
influenza
c
least
common
serotyp
found
pathogen
agent
sporad
report
influenza
virus
b
respons
approxim
communityacquir
viral
pneumonia
adult
impact
greater
elderli
atrisk
popul
pregnant
women
immunocompromis
patient
patient
chronic
diseas
especi
heart
lung
diseas
recent
subtyp
influenza
known
swineflu
agent
emerg
import
threaten
pandem
sever
affect
immunosuppress
patient
transplant
recipi
highrisk
popul
pregnant
women
obes
patient
heart
lung
diseas
affect
individu
gener
younger
affect
season
influenza
estim
approxim
death
april
januari
accord
estim
world
health
organ
brazil
admit
patient
requir
admiss
intens
care
unit
total
requir
mechan
ventil
mortal
rate
countri
death
per
inhabit
infect
influenza
viru
lead
cell
death
especi
upper
airway
viru
infect
lower
airway
directli
may
bleed
without
proport
accumul
inflammatori
cell
also
mucociliari
clearanc
impair
may
determin
bacteri
adher
respiratori
epithelium
impair
function
tcell
macrophag
neutrophil
also
occur
lead
decreas
host
defens
event
togeth
facilit
frequent
observ
concomit
bacteri
infect
incub
period
one
two
day
symptom
typic
last
three
five
day
three
clinic
present
primari
influenza
pneumonia
influenza
infect
secondari
bacteri
pneumonia
simultan
coinfect
viral
bacteri
primari
pneumonia
manifest
persist
cough
pain
throat
headach
myalgia
five
day
associ
onset
progress
dyspnea
cyanosi
less
common
albeit
sever
present
influenza
pneumonia
secondari
bacteri
infect
character
intensif
high
fever
cough
purul
sputum
initi
improv
associ
appear
new
opac
chest
radiographi
main
agent
involv
streptococcu
pneumonia
staphylococcu
aureu
haemophilu
influenza
pneumonia
caus
viral
bacteri
coinfect
manifest
similarli
pneumonia
secondari
bacteri
infect
initi
improv
context
viru
bacteri
agent
isol
togeth
microbiolog
analysi
inflammatori
marker
creactiv
protein
procalcitonin
also
littl
use
differenti
bacteri
viral
pneumonia
sever
case
observ
pandem
show
high
level
two
substanc
patient
viral
pneumonia
pulmonari
radiolog
alter
nonspecif
seen
perihilar
peribronchi
opac
consolid
diffus
bilater
interstiti
opac
especi
sever
form
diseas
neutropen
patient
fig
influenza
viru
isol
sputum
nasal
lavag
nasal
pharyng
swab
lower
yield
latter
cultur
medium
posit
cultur
detect
within
three
day
inocul
remaind
seventh
day
rapid
test
high
specif
influenza
amantadin
rimantadin
approv
prevent
treatment
effect
influenza
b
work
block
ion
channel
viral
protein
inhibit
decapsul
use
indic
within
hour
symptom
onset
uncompl
case
effect
test
sever
pneumonia
furthermor
mani
strain
resist
drug
thu
recommend
empir
singledrug
therapi
oseltamivir
zanamivir
drug
block
surfac
protein
neuraminidas
trap
viru
within
infect
respiratori
epithelium
prevent
dissemin
prefer
administ
within
hour
symptom
onset
activ
influenza
b
low
potenti
induc
resist
although
case
describ
unit
state
pandem
case
sever
pneumonia
medic
provid
even
hour
symptom
onset
potenti
fatal
respiratori
failur
mani
case
pandem
rescu
maneuv
refractori
hypoxemia
recruit
ventil
prone
posit
may
institut
combin
antivir
therapi
rsv
part
paramyvirida
famili
common
caus
lower
respiratori
infect
children
current
identifi
import
caus
pneumonia
adult
especi
elderli
becom
second
frequent
caus
among
virus
found
popul
rsv
highli
contagi
spread
droplet
fomit
popul
risk
consist
mainli
children
younger
six
month
patient
chronic
diseas
cystic
fibrosi
patient
congenit
heart
diseas
institution
elderli
individu
immunosuppress
patient
overal
mortal
adult
vari
accord
immun
statu
healthi
adult
bone
marrow
transplant
recipi
virus
b
low
sensit
noteworthi
suspect
case
test
recommend
rtpcr
analysi
greater
diagnost
use
histolog
assess
anoth
possibl
diagnost
option
achiev
ultrastructur
analysi
lung
biopsi
treatment
must
perform
support
measur
supplement
oxygen
analges
antipyret
antivir
therapi
select
case
drug
approv
treatment
influenza
infect
amantadin
rimantadin
oseltamivir
zanamivir
tabl
rsv
rare
diagnos
adult
infect
character
persist
symptom
upper
airway
runni
nose
earach
sore
throat
associ
prolong
cough
whether
dri
product
dyspnea
wheez
may
caus
bronchiti
bronchiol
sever
pneumonia
requir
mechan
ventil
compar
influenza
viru
infect
higher
frequenc
rhinorrhea
purul
sputum
observ
well
lower
frequenc
fever
gastrointestin
symptom
inflammatori
marker
obtain
airway
blood
solubl
intercellular
adhes
molecul
type
interleukin
test
children
appear
show
posit
correl
higher
concentr
sever
durat
hospit
pulmonari
radiolog
find
associ
rsv
infect
nonspecif
bilater
alveolar
opac
interstiti
alter
describ
case
similar
observ
influenza
viru
infect
viru
isol
cultur
highest
yield
found
sampl
nasopharyng
lavag
tracheal
secret
immunosuppress
patient
posit
cultur
found
nasopharyng
lavag
sampl
tracheal
secret
bronchoalveolar
lavag
rapid
test
detect
viral
antigen
sensit
high
specif
gene
amplif
rtpcr
also
avail
ribavirin
work
prevent
viral
transcript
current
avail
antivir
drug
treatment
rsv
pneumonia
tabl
current
recommend
medic
consid
sever
case
patient
high
risk
complic
intraven
immunoglobulin
specif
rsv
palivizumab
also
use
combin
ribavirin
criticallyil
patient
high
risk
complic
especi
bone
marrow
transplant
recipi
adenoviru
highli
contagi
dna
viru
differ
serotyp
adenoviru
infect
occur
time
year
account
approxim
pneumonia
children
histor
viru
also
identifi
import
caus
agent
respiratori
infect
outbreak
militari
base
unit
state
serotyp
classifi
seven
subgroup
speci
g
pulmonari
infect
caus
predominantli
serotyp
although
viru
determin
low
mortal
subtyp
caus
sever
respiratori
failur
suscept
patient
solidorgan
transplant
recipi
individu
hiv
infect
patient
type
impair
cell
immun
although
report
fatal
case
postop
period
cardiac
surgeri
previous
immunocompet
patient
adenoviru
dissemin
occur
direct
inocul
conjunctiva
aerosol
fece
fomit
viru
capabl
surviv
contamin
area
environ
sever
week
viral
reactiv
also
occur
immunosuppress
patient
result
sever
clinic
syndrom
includ
keratoconjunct
gastroenter
hepat
hemorrhag
cystiti
associ
pneumonia
pneumonia
mortal
rate
rang
especi
bone
marrow
transplant
recipi
clinic
pictur
character
fever
cough
runni
nose
sore
throat
tonsil
otiti
media
mean
durat
three
five
day
leukocytosi
elev
inflammatori
activ
observ
import
differenti
bacteri
infect
pulmonari
opac
often
reticulonodular
radiolog
imag
consolid
also
observ
respiratori
secret
cultur
perform
confirm
diagnosi
demonstr
cytopath
effect
two
day
onset
serotyp
diagnos
rapid
antigen
detect
pcr
techniqu
especi
immunosuppress
patient
control
studi
regard
best
treatment
option
drug
adequ
specif
clinic
syndrom
thu
use
antivir
base
recommend
expert
case
report
drug
use
ribavirin
cidofovir
ganciclovir
vidarabin
larger
number
report
favor
combin
therapi
cidofovir
ribavirin
especi
patient
histori
unfavor
evolut
bone
marrow
transplant
tabl
hpiv
paramyxoviru
classifi
four
subtyp
viru
second
common
caus
viral
infect
children
account
approxim
respiratori
infect
also
identifi
caus
agent
pneumonia
adult
mainli
hpiv
serotyp
transmiss
occur
direct
contact
infect
host
respiratori
droplet
fomit
instal
infect
caus
secret
high
level
inflammatori
cytokin
interferon
alpha
tumor
necrosi
factor
alpha
tnfalpha
mediat
respons
abund
product
mucu
respiratori
epithelium
submucos
edema
vocal
cord
determin
partial
obstruct
upper
airway
characterist
stridor
diseas
incub
period
last
one
three
day
characterist
symptom
croup
hoars
stridor
steepl
sign
common
children
less
preval
immunocompet
adult
primari
strain
caus
bronchiol
pneumonia
lead
onset
nonspecif
symptom
fever
runni
nose
wheez
dri
cough
dyspnea
symptom
mimic
number
respiratori
infect
especi
immunosuppress
individu
identif
mark
upper
airway
involv
sinus
stridor
import
clue
diagnosi
report
bronchiol
obliteran
organ
pneumonia
giantcel
pneumonia
also
describ
infect
agent
radiolog
point
view
alter
often
observ
focal
alveolar
opac
although
diffus
interstiti
pattern
also
describ
previou
studi
show
infect
may
associ
presenc
multipl
noncavit
nodul
mm
peribronchi
distribut
isol
cultur
carri
prefer
nasal
secret
rtpcr
faster
sensit
diagnost
method
support
care
usual
enough
specif
therapi
recommend
patient
high
risk
sever
symptom
case
agent
choic
base
vitro
studi
case
studi
oral
aerosol
ribavirin
tabl
advanc
diagnost
method
greater
access
pcr
agent
metapneumoviru
rhinoviru
coronaviru
current
recogn
caus
communityacquir
pneumonia
human
metapneumoviru
rel
new
viru
respiratori
pathogen
initi
describ
netherland
viru
belong
famili
rsv
hpiv
usual
acquir
earli
childhood
caus
bronchiol
croup
pneumonia
reinfect
occur
adulthood
sever
case
affect
elderli
individu
heart
lung
diseas
immunocompromis
patient
incub
period
approxim
five
day
clinic
pictur
similar
virus
nasal
congest
cough
wheez
fever
dyspnea
hoars
common
find
rsv
infect
chest
imag
show
bilater
alveolar
opac
case
nodular
opac
pleural
effus
also
occur
difficult
viru
isol
cultur
extrem
slow
replic
rate
rtpcr
method
choic
diagnosi
treatment
yet
well
establish
use
ribavirin
alon
combin
immunoglobulin
appear
promis
sever
case
coronavirus
recogn
caus
pneumonia
seriou
epidem
china
four
human
subtyp
recogn
incub
period
coronavirusassoci
infect
two
five
day
common
symptom
myalgia
chill
dyspnea
possibl
progress
respiratori
failur
fever
uncommon
find
may
observ
thrombocytopenia
elev
level
transaminas
ddimer
radiolog
pattern
nonspecif
commonli
demonstr
diffus
pulmonari
groundglass
opac
chest
tomographi
case
pneumomediastinum
also
report
case
sever
outcom
proteas
inhibitor
lopinavir
ritonavir
interferonalpha
beta
administ
evid
efficaci
ribavirin
use
rhinoviru
member
picornavirida
famili
major
caus
cold
gener
popul
second
preval
agent
caus
bronchiol
pediatr
popul
studi
shown
agent
often
relat
exacerb
asthmat
children
although
controversi
studi
shown
preval
viru
case
sever
pneumonia
hospit
intens
care
diagnosi
difficult
attain
pcr
techniqu
method
serolog
test
cultur
feasibl
rapid
detect
antigen
standard
observ
recent
publish
studi
virus
increasingli
consid
caus
seriou
respiratori
infect
coinfect
even
immunocompet
patient
context
essenti
consid
presenc
pathogen
potenti
caus
lung
diseas
increas
capac
identifi
togeth
greater
possibl
diagnos
viral
infect
feasibl
increas
knowledg
epidemiolog
profil
viral
communityacquir
pneumonia
also
plan
better
therapeut
prevent
strategi
societi
